Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
Conditions
Keywords
non-chronic migraine, migraine prevention
Brief summary
It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
Interventions
DRUGBGG492
DRUGPlacebo
In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Male and female smoking and non-smoking subjects of 18 to 65 years of age (inclusive) * Patients diagnosed with non-chronic migraine with or without aura of duration of at least 12 months prior to the study start * Patient diagnosed with migraine (according to the International Headache Society categories 1.1 and with equal to/more than 3 and equal to/ less than 12 migraine attacks per 4 weeks for each of the last 6 months preceding the Screening * Patients willing to abstain from activities that require focused attention, e.g. driving a car or other vehicles, operating machines or engaging in potentially dangerous activities that require focused attention and intact physical balance
Exclusion criteria
* Patients diagnosed with basilar, ophthalmoplegic or hemiplegic migraine as shown in the current/past medical history. * Patients having an experience of non-migraine headaches on more than 6 days per 4 weeks in the past 6 months prior to study start * Patients receiving regular treatment during the four (4) weeks preceding the Baseline with psychoactive drugs (e.g. hypnotics, benzodiazepines, neuroleptics) except antidepressants (eg. SSRIs, SNRIs, Tri- or Tetracyclics). * Patients receiving migraine prevention medications during past three (3) months preceding Baseline * Patients receiving topiramate as migraine prevention medication during past six (6) months preceding Baseline * Patients receiving metamizole as acute treatment of migraine during past three (3) months preceding Baseline * Patients using (or having used within four (4) weeks before the treatment start) drug treatments that are potent inhibitors of OATP transporters (e.g. rifampin). * Any psychiatric condition (e.g., schizophrenia, dementia, bipolar disorder) as shown in the past medical history prior to study start * Patients with recent (within the last three \[3\] years prior to study start) and/or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, orthostatic hypotension etc.). * Pregnant or nursing (lactating) women. Baselines (1 and 2). * Patients with history of drug or alcohol abuse within the 12 months prior to dosing Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of migraine attacks | 12 weeks | 50% responder rate (equal to or more than 50 % reduction in attack frequency during the last 4-weeks of the 12-weeks treatment period compared with the 4-weeks Baseline period) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of migraine attacks | 12 weeks | Mean change in number of migraine attacks comparing the last 4-weeks treatment with the Baseline period. |
Outcome results
None listed